Jpmorgan Chase & CO Maxcyte, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MXCT
# of Institutions
118Shares Held
65.1MCall Options Held
600Put Options Held
2.7K-
Black Rock Inc. New York, NY8.14MShares$30.6 Million0.0% of portfolio
-
Cadian Capital Management, LP New York, NY7.62MShares$28.7 Million1.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$21.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.18MShares$19.5 Million0.01% of portfolio
-
Vitruvian Partners LLP5.04MShares$19 Million5.8% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $382M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...